Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer

Cerulli, C.; Sciarra, Alessandro; Salvatori, G.; Silverio, F. Di

doi:10.1016/j.urology.2004.06.066

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of estramustine (420 mg/day) plus lanreotide (73.9 mg i.m.) every 4 weeks lead to a long-term survival in 1 patient; his marker of neuroendocrine differentiation, chromogranin A, was 816 ng/ml and came down to 12 ng/ml with a lasting PSA of 0.1 ng/ml [40] . In a randomized phase-II trial Dimopoulos et al [41] compared the efficacy of estramustine plus 100 mg etoposide for 21 days versus 30 mg lanreotide i.m.…”

Section: Combination Therapymentioning

confidence: 99%

Growth Hormone Inhibitors in Prostate Cancer: A Systematic Analysis

2008

View full text Add to dashboard Cite

Objective: Despite initial therapeutic success through androgen ablation in patients with advanced prostate cancer, the vast majority progress to androgen independence. Somatostatin (SST) analogs are a viable therapeutic modality before resorting to chemotherapy or immunotherapy. Their mechanism of action is related to a reduction in the IGF-1 (survival factor, reaction on neuroendocrine cells) appearing incrementally after long-term androgen deprivation and a possible suppression of GnRH receptors in prostate cancer following exposure to LHRH agonists. Methods: The computerized databases Medline, NCBI and OMIM were searched for the terms, somatostatin and prostate cancer, in parallel with printed bibliographic references. Forty-two studies were included and 267 patients with androgen-independent prostate cancer (AIPC) who were treated with SST analogs alone or in combination with other medications, e.g. dexamethasone, were analyzed. Results: In 42 studies with 267 AIPC patients, SST analogs were found to be effective, particularly when combined with estrogens or corticosteroids. The side effects are mild and related to the gastrointestinal tract. Conclusions: It would be interesting to study SST analogs in randomized trials including patients with well-defined AIPC. Whether SST analogs could be given earlier during sequential hormonal therapy remains to be studied.

show abstract

Section: Combination Therapymentioning

confidence: 99%